GleamWall
中文EN

DRUG BRIGHT MINDS BIOSCIENCES INC. IFRS

Pharmaceutical Preparations · Nasdaq · SEC CIK 1827401 · Reporting currency CAD · Fiscal year ends 09/30

Financial factors as of 2024-09-30 (FY2024), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY—
TTM net income YoY62.0%
TTM EPS YoY67.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-46.2%
ROA-43.2%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets9.3%
Debt / equity0.00x
Current ratio11.32x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.66x
Accruals ratio-14.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Unit: CAD 2019Q4*2019-09-30
Income statement
Revenue—
R&D expense42,009
SG&A expense0
Net income-78,717
EPS (basic)-0.04
EPS (diluted)-0.04
Balance sheet
Cash & equivalents79,991
Total assets—
Shareholders' equity45,283
Cash flow statement
Operating cash flow-42,009
Financing cash flow122,000
Stock-based compensation0

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· Amounts are in the company's reporting currency, CAD, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.